All In MedTech

Device Trial Radar · NCT04224155

Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction

A Prospective, Multicenter, Randomized, Masked, Controlled Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction

Last checked: Nov 19, 2026Latest source record: Oct 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Mar 10, 2020

Primary completion

Jun 14, 2022

Study completion Jun 14, 2022

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedNot on our public-company list
Sponsor type
Industry
First posted
Jan 13, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and performance of the enVista trifocal intraocular lens when implanted in the capsular bag.

Conditions

  • Cataract

Interventions

  • enVista MX60EFH trifocal intraocular lenses (IOLs)Device

    enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally

  • enVista MX60E monofocal intraocular lenses (IOLs)Device

    enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serious Adverse EventsTime frame: Day 120 to Day 180 after second eye IOL implantation
  2. Cumulative Rate of Secondary Surgical Interventions Due to the Optical Properties of the LensTime frame: Day 120 to Day 180 after second eye IOL implantation
  3. Photopic Uncorrected Distance Visual Acuity (UDVA) for First Implanted EyesTime frame: Day 120 to Day 180 after second eye IOL implantation

2 more outcomes with a free account

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Site 106

    Calgary, Alberta, Canada

  • Bausch Site 102

    Concord, Ontario, Canada

  • Bausch Site 103

    Mississauga, Ontario, Canada

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.